Regulus Therapeutics GAAP EPS of -$0.21 misses by $0.04

seekingalpha
08 Nov 2024
  • Regulus Therapeutics press release (NASDAQ:RGLS): Q3 GAAP EPS of -$0.21 misses by $0.04.
  • Ended third quarter 2024 with cash, cash equivalents, and investments of $87.3 million; Cash runway into H1 2026

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10